glp-1 roche Ad hoc announcement pursuant to Art. 53 LR] announces positive Phase I results of its oral receptor agonist CT-996 for the treatment of people with obesity Roche, trailing in obesity, showcases
Pay in 4 interest-free payments of $7.34 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
![glp-1 roche Ad hoc announcement pursuant to Art. 53 LR] announces positive Phase I results of its oral receptor agonist CT-996 for the treatment of people with obesity Roche, trailing in obesity, showcases](https://imgproxy.divecdn.com/Uen3WaSRQrS4Q4Ruldy39jm7wp7yZKOh-bFeEbuMcFE/g:ce/rs:fill:1200:675:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTUwMDMzMjU3LmpwZw==.webp)
![glp-1 roche Ad hoc announcement pursuant to Art. 53 LR] announces positive Phase I results of its oral receptor agonist CT-996 for the treatment of people with obesity Roche, trailing in obesity, showcases](https://www.statnews.com/wp-content/uploads/2019/08/GettyImages-463683050-645x645.jpg)
![glp-1 roche Ad hoc announcement pursuant to Art. 53 LR] announces positive Phase I results of its oral receptor agonist CT-996 for the treatment of people with obesity Roche, trailing in obesity, showcases](https://www.reuters.com/resizer/v2/F33QVZHAVJKINCYYAWNRZGPP2I.jpg?auth=2bf5c4f15a6a09c7e4a68854c7ccf2ea81d0ea0834b9192fb9d93fb1cd369b7a)
![glp-1 roche Ad hoc announcement pursuant to Art. 53 LR] announces positive Phase I results of its oral receptor agonist CT-996 for the treatment of people with obesity Roche, trailing in obesity, showcases](https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/Structure%20support.jpg?VersionId=IqhUtEq847RmKGNDTcDf7PW7BmOaxUZU)





















